BACKGROUND: Anthracycline-related heart failure is a leading cause of morbidity in survivors of adult-onset lymphoma. There is a paucity of information on screening for late-occurring preclinical disease, which, in turn, has limited guidelines for early detection and intervention. The objectives of this study were to examine the prevalence and risk of cardiac dysfunction, as measured by echocardiography (abnormal left ventricular systolic/diastolic function or strain), in lymphoma survivors who received treatment with anthracyclines and to evaluate the diagnostic yield of blood biomarkers in the asymptomatic setting. METHODS: Lymphoma survivors who underwent hematopoietic cell transplantation (HCT) (n 5 78) or received conventional therapy (non-HCT; n 5 77) were compared with each other and with a group of matched controls (n 5 51); the study was limited to lymphoma survivors who were >5 years from diagnosis. RESULTS: At a median follow-up of 9.4 years after diagnosis, 1 in 5 (20.6 %) lymphoma survivors had cardiac dysfunction; the odds of having cardiac dysfunction were 6.6-fold greater (odds ratio [OR], 6.6; P 5.01) among lymphoma survivors compared with matched controls. There was a dose-dependent risk of cardiac dysfunction according to the cumulative anthracycline dose (controls [referent group], 1-249 mg/m 2 [OR, 4.7; P 5.05], and 250 mg/m 2 [OR, 7.6; P <.01]), but there was no difference in the prevalence of cardiac dysfunction between conventionally treated and HCT survivors. The diagnostic accuracy of cardiac blood biomarkers in the asymptomatic setting was quite poor. CONCLUSIONS: In these long-term survivors, there was a high rate of cardiac dysfunction that was independent of HCT status. The growing number of lymphoma survivors makes it imperative to identify reliable and cost-effective strategies to decrease the burden of heart failure in this population. Cancer 2018;124:850-7.
INTRODUCTION
Anthracyclines form the backbone of therapy for lymphoma. However, the use of anthracyclines is limited by a dosedependent cardiotoxicity, which can result in heart failure either during treatment or years after the completion of therapy. 1 It is believed that anthracycline cardiotoxicity is related to direct injury to the cardiomyocytes because of a combination of free radicals and intracardiac metabolic derangements. 2 The characteristically delayed manifestation of symptomatic heart failure in cancer survivors is likely related to the eventual failure of a reduced number of unhealthy cardiomyocytes in response to the myocardial injury. 3 In this context, anthracycline-related heart failure can be characterized as a progressive disorder, with a variable period of asymptomatic cardiac dysfunction that precedes clinically overt disease. 1 Therefore, several clinical guidelines recommend routine screening with echocardiography for asymptomatic cardiac dysfunction, allowing for the implementation of appropriate interventions (eg, angiotensin-converting enzyme inhibitors, bblockers) to prevent or delay the onset of symptomatic disease. [4] [5] [6] These recommendations emphasize the importance of screening for systolic as well as diastolic dysfunction during anthracycline therapy, and for the need to incorporate novel echocardiographic features (eg, global longitudinal strain) and blood biomarkers (eg, natriuretic peptides) of cardiac dysfunction, when feasible. [4] [5] [6] The recommendations regarding long-term surveillance (beyond the immediate treatment period) are less clear.
Indeed, the recent American Society of Clinical Oncology guideline for the prevention and monitoring of cardiac dysfunction 5 could not provide guidance on screening in long-term (>5 years from diagnosis) cancer survivors because of the paucity of information on the prevalence and risk factors for cardiac dysfunction in this population. In addition, although blood biomarkers are routinely used to diagnose acute heart failure in the general nononcology population, 7, 8 little is known about their diagnostic utility in asymptomatic long-term cancer survivors; therefore, no recommendations could be made in the American Society of Clinical Oncology guideline regarding their use during routine surveillance. 5 Keeping these knowledge gaps in mind, in the current study, we sought to compare the prevalence and risk of cardiac dysfunction in long-term lymphoma survivors treated with anthracyclines with agematched and sex-matched noncancer controls. Secondary objectives were to compare the prevalence of cardiac dysfunction in conventionally treated survivors with those who had undergone hematopoietic cell transplantation (HCT)-a population thought to be at higher risk of cardiac dysfunction 9, 10 -and to evaluate the diagnostic accuracy of candidate blood biomarkers for the detection of asymptomatic disease in lymphoma survivors.
MATERIALS AND METHODS

Study Participants
A cross-sectional study design was used. Patients were identified from an existing electronic database at a single institution that included information on cancer diagnosis, age at diagnosis, and vital status. Eligibility criteria included: 1) diagnosis of non-Hodgkin lymphoma or Hodgkin lymphoma between January 1995 and December 2009; 2) age 21 years at the time of diagnosis; 3) 5 years from diagnosis; 4) known to be alive at the time of recruitment (from September 2013 to July 2015); 5) off cancer therapy for 2 years; and 6) received anthracycline-based treatment for lymphoma. We excluded survivors who were actively being treated for cardiomyopathy or heart failure, because echocardiographic indices or blood biomarkers in these individuals could have been altered by pharmacologic therapy. In total, 678 survivors met the eligibility criteria, and 200 (30%) were randomly selected for recruitment, stratified on age at enrollment (65 years), sex, HCT status (1:1), and time from diagnosis (62 years). There were no significant demographic or treatment-related differences between the subset that was selected for recruitment and the remaining cohort (Supporting Table 1 ; see online supporting information).
Healthy control participants without a history of cancer or cardiomyopathy were recruited from the general population (friends, acquaintances of study participants) and were frequency-matched (1:3) to lymphoma survivors on sex and age (65 years) at the time of study participation. The study was approved by the City of Hope Institutional Review Board, and all study participants provided written informed consent.
Cardiac Evaluation
Echocardiograms were performed by a designated study technician and consisted of complete, 2-dimensional, Mmode, and Doppler evaluations, according to American Society of Echocardiography and European Association of Cardiovascular Imaging practice guidelines. 4 A General Electric Vivid-7 echocardiography machine (General Electric, Chicago, IL) was used for all study-related echocardiographic evaluations. Left ventricular (LV) end diastolic and systolic diameters, interventricular septal thickness, and LV posterior wall thickness in diastole and systole were measured on M-mode recordings obtained from a standard LV parasternal view. The LV ejection fraction (EF) was calculated from the apical 4-chamber and 2-chamber views using a modified Simpson biplane method.
11 LV mass was calculated from the recommended American Heart Association/American College of Cardiology formula, 11 which takes into consideration LV dimension, posterior wall and intraventricular septal thickness, and correction factors derived from regression analysis, divided by body surface area. Measurements of LV diastolic function included pulsed Doppler measurement of mitral valve inflow, peak velocities of early filling (E-wave) and filling during atrial systole (A-wave), mitral annular myocardial e 0 and a 0 velocities, and mitral E/A and E/e 0 ratios. LV global longitudinal strain (GLS) was measured manually by tracing the endocardial border in end systole. Commercially available analysis software (EchoPAC version BT08; GE Healthcare, Little Chalfont, UK) was used to automatically trace regions of interest as well as the entire myocardium. Study echocardiograms were first interpreted by a designated cardiologist at our institution to ensure there was not a clinically actionable finding. Then, an anonymized copy of the digitized echocardiogram was sent to the study core cardiology laboratory (University of Toronto, Toronto, ON), where all study endpoints were re-measured by a single sonographer who was blinded to the lymphoma survivor or control status of the study participant. All measurements were based on the average of 3 cardiac cycles, in accordance with established criteria of the American Society of Echocardiography. 12 Intraobserver and interobserver comparisons were made in 15 randomly selected study participants (correlation coefficient: range, 0.81-0.99) (Supporting Table 2 ; see online supporting information). 
Blood Biomarkers
Blood samples were collected on the day of the echocardiographic assessment. B-type natriuretic peptide (BNP) was measured using the Triage BNP Test (Beckman Coulter, Fullerton, CA; measurable range, 2.0-5000 pg/ mL). Levels of N-terminal prohormone of BNP (NTproBNP) were measured using the Elecsys proBNP II test (Roche Diagnostics, Indianapolis, IN; lower limit of detection, 5 pg/mL). Protein ST2 levels were measured using the Presage ST2 enzyme-linked immunosorbent assay (ELISA) test (Critical Diagnostics, New York, NY; lower limit of detection, 2.0 ng/mL).
Clinical Data Collection and Definitions
Self-reported questionnaires were used to obtain baseline data on sociodemographic variables (age, sex, race/ethnicity, highest level of education, employment status, and marital status) and cardiovascular risk factors. Individuals were noted to have hypertension, diabetes, or dyslipidemia if they were receiving medications for the management of those conditions at the time of study enrollment. Overweight/obese was defined as a body mass index 25 kg/m 2 . Physical inactivity was defined as not meeting the national guidelines for regular exercise for adults (eg, 3-5 sessions of moderate-intensity or vigorous-intensity exercise per week of 20 minutes' duration). 13 Medical records provided the following information: date of diagnosis, type of cancer, cumulative dose of anthracycline exposure, receipt and dose of chest-directed radiation therapy (RT), and HCT status. Chest-directed RT included radiation to the following fields: mantle, mediastinal, or lung. 10 High-dose (HD) anthracycline was defined as a cumulative doxorubicin dose 250 mg/m 2 , 5 and HD chest RT was defined as receipt of 30 grays. 5 
Statistical Analysis
The primary endpoint for this study was cardiac dysfunction, defined a priori as having either LV systolic dysfunction (LV EF, < 50%), 14 diastolic dysfunction (mitral E/e 0 , > 14), 15 or abnormal strain (GLS, > 216). 16 The prevalence of cardiac dysfunction was projected to be from 20% to 25% for survivors and 5% for controls. Assuming a Type I error of 0.05, enrolling approximately 150 survivors and 50 controls provided a minimum of 80% power to detect a significant difference in the prevalence of cardiac dysfunction between the groups.
Descriptive statistics for clinical variables, echocardiographic indices, and blood biomarkers were generated for study participants. Categorical variables were compared using chi-square tests. Continuous variables were compared using independent 2-sample t tests or analyses of variance. Sensitivity, specificity, positive predictive value, and negative predictive value were calculated to assess the validity of blood biomarkers for the detection of cardiac dysfunction among lymphoma survivors. Cutoff levels for blood biomarkers (abnormal: BNP, 100 pg/ dL; NT-proBNP, 300 pg/dL; ST-2, > 35 ng/mL) were based on the thresholds used to diagnose cardiac dysfunction in the general population. [17] [18] [19] Multivariable, unconditional logistic regression was used to identify variables that were associated with cardiac dysfunction. The dependent variable was cardiac dysfunction. The independent variables included clinical and treatment-related factors that differed between the 3 groups (P < .1), as well as variables thought to impact the risk of cardiac dysfunction, and included age at examination and body mass index. A separate regression model was created to evaluate the association between cardiac dysfunction and cumulative anthracycline dose (0, 1-249 mg/m 2 , or 250 mg/m 2 ). Data were analyzed using SPSS version 18.0 (IBM Corporation, Armonk, NY). All statistical tests were 2-sided, and P values < .05 were considered statistically significant.
RESULTS
Patient Characteristics
Two hundred survivors were approached to participate in the study. Twenty-nine individuals refused participation, and 16 others did not complete the full battery of echocardiographic and blood biomarker testing or had incomplete echocardiographic measurements. The current report includes results from 155 study participants who completed all study measurements and had evaluable echocardiograms (participation rate, 78%). Table 1 summarizes the participants' characteristics. Because of previously established matching criteria, there were no statistically significant differences by sex or age at study enrollment between lymphoma survivors and controls. In addition, there were no differences in race/ethnicity, sociodemographics (education, marital status, employment), or prevalence of cardiovascular risk factors (overweight/obese, hypertension, diabetes, dyslipidemia, smoking history, physical activity level) between survivors and controls.
Among lymphoma survivors, the median time from diagnosis to study participation was 9.4 years (range, 5.0-19.9 years). One hundred nine survivors (70.3%) had received treatment with HD anthracycline, and 16 (10.3%) had received HD chest RT. Because of study design, one-half of survivors (50.3%) had undergone Original Article autologous HCT for the management of their lymphoma. HCT survivors were significantly less likely to have received HD chest RT (6.4% vs 14.3%; P 5 .02) compared with conventionally treated patients (Supporting Table 3 ; see online supporting information). There was no difference in cancer diagnosis, age at diagnosis, time from diagnosis, or cumulative anthracycline dose between the HCT and conventionally treated survivors. It is noteworthy that none of the survivors had clinical signs or symptoms of heart failure 7 at the time of study evaluation.
Echocardiographic Assessment
A comparison of echocardiographic measurements of LV systolic function, diastolic function, and GLS between HCT survivors and conventionally treated survivors as well as controls is presented in Table 2 . Overall, survivors were significantly more likely to have a larger LV diameter in systole, decreased LV posterior wall thickness in systole, lower EF, increased mitral E/e 0 , and decreased GLS compared with controls. Conversely, there was no difference in echocardiographic indices by HCT status. In lymphoma survivors, the prevalence of abnormal EF, diastolic dysfunction, and abnormal GLS was 8.4%, 5.2%, and 14.2%, respectively. The overall prevalence of cardiac dysfunction was significantly greater in lymphoma survivors compared with controls (20.6% vs 3.9%; P < .01). Among survivors who had cardiac dysfunction (N 5 32), the vast majority (75%) had an abnormality in only 1 parameter, and there was concordance (abnormal in all 3 indices) in 6.3% of individuals. In multivariable logistic 
Blood Biomarkers
Candidate biomarkers of cardiac remodeling were compared across all 3 groups (Table 2) . Lymphoma survivors had significantly higher BNP (42 pg/dL) and NTproBNP (124 pg/dL) levels compared with controls (BNP, 29 pg/dL; P < .01; NT-proBNP, 44 pg/dL). There were no statistically significant differences in BNP or NT-proBNP levels between conventionally treated and HCT survivors or in ST-2 levels across all 3 groups. The sensitivity of blood biomarkers ranged from 6% (ST-2) to 28% (BNP); specificity ranged from 86% (NT-proBNP) to 89% (BNP, ST-2); the positive predictive value ranged from 15% (ST-2) to 41% (BNP), and the negative predictive value ranged from 78% (ST-2) to 83% (BNP) ( Table 3 ). There was no improvement in the diagnostic accuracy of blood biomarkers according to cardiac dysfunction type (systolic, diastolic, abnormal GLS) or by different cutoff levels (BNP, 50 pg/dL 20 ; Abbreviations: BNP, B-type natriuretic peptide; HCT, hematopoietic cell transplantation; LV, left ventricular; NT-pro-BNP, N-terminal prohormone of brain natriuretic peptide. a Cardiac dysfunction was defined as having either LV systolic dysfunction (LV ejection fraction < 50%), diastolic dysfunction (mitral E/e 0 > 14), or abnormal strain (global longitudinal strain > 216).
NT-proBNP, 125 pg/dL 21 (Supporting Table 4 ; see online supporting information).
DISCUSSION
The principal findings from the current study were that 1 in every 5 long-term lymphoma survivors who had received anthracyclines had asymptomatic cardiac dysfunction, and the odds of having cardiac dysfunction were 7-fold greater among lymphoma survivors compared with age-matched and sex-matched controls without a history of cancer. We confirmed a dose-dependent increased risk of cardiac dysfunction by cumulative anthracycline dose but observed no difference in the prevalence or severity of cardiac dysfunction between conventionally treated and HCT survivors. Finally, although levels of cardiac blood biomarkers generally were higher in survivors who had cardiac dysfunction compared with those who had normal function, the diagnostic accuracy of these biomarkers in the asymptomatic setting was limited. The findings from the current study can be used for the development of targeted, long-term screening strategies in at-risk survivors as well as interventional studies in at-risk survivors aimed at improving cardiac function and preventing symptomatic heart failure, with its attendant morbidity.
Large cohort studies have reported a 2-fold to 5-fold increased risk of symptomatic heart failure in lymphoma survivors compared with the general population. 10, [22] [23] [24] The latency of disease in these studies has varied (from months to years) according to study design, differences in definitions used for the primary outcome, and treatment characteristics. Until now, very little was known about the prevalence of asymptomatic cardiac dysfunction in these long-term survivors. Recent studies have suggested that lymphoma survivors who have undergone autologous HCT may be at an especially high risk of developing symptomatic heart failure, 9, 10 which is attributed to additional HCT-related conditioning chemotherapy and/or radiation exposures in this population. To our knowledge, no study has compared the prevalence of asymptomatic cardiac dysfunction in HCT survivors with that in conventionally treated patients, and few have compared the prevalence with that in the general population. 5, 25 The survivors in the current study were representative of the larger contemporary cohort of patients with lymphoma who receive treatment with anthracyclines at our institution. Cumulative anthracycline exposure was equivalent between conventionally treated and HCT survivors, and we observed no difference in echocardiographic measures of cardiac function between the 2 groups. Not surprisingly, the odds of having cardiac dysfunction in the current study (OR, 6.6) was comparable to that reported in a recent study of long-term lymphoma survivors who had undergone HCT (OR, 6.6), 9 suggesting that our findings may be broadly applicable to other populations of anthracycline-exposed lymphoma survivors, regardless of HCT status.
Traditionally, detection of anthracycline-related cardiotoxicity has relied upon echocardiographic screening of LV systolic function such as EF. 26 However, LV EF has been increasingly recognized as a late-occurring measure of cardiac dysfunction, 27, 28 and a poor predictor of future symptomatic disease. 29 It is noteworthy that reliance on LV EF alone ignores the possibility of diastolic dysfunction in the setting of preserved EF. Newer echocardiographic parameters such as GLS may complement traditional measures of systolic and/or diastolic function, allowing more accurate prediction of future symptomatic disease. 4, 6 For example, in breast cancer patients, screening strategies that incorporate EF plus GLS have nearly twice the predictive power for future symptomatic disease when compared EF alone. 30, 31 The current study is the first to use a comprehensive screening approach (systolic, diastolic, GLS) to assess cardiac function in anthracyclineexposed lymphoma survivors treated as adults, using readily available echocardiographic screening modalities. The thresholds used to define systolic dysfunction (LV EF, < 50%), 14 diastolic dysfunction (mitral E/e 0 , > 14), 15 or abnormal strain (GLS, > 216) 16 have been well established in the general nononcology community, and further supported by the low abnormal prevalence (range, 0% to 4%) seen in our control population. Surprisingly, we found that survivors treated with relatively modest doses of anthracyclines (1-249 mg/m 2 ) had a nearly 5-fold risk of cardiac dysfunction when compared with controls, suggesting that screening should not be limited to survivors treated with HD-anthracyclines alone. Importantly, there was little concordance between echocardiographic parameters (LV EF, mitral E/e 0 , GLS) in survivors with cardiac dysfunction, emphasizing the need for multifaceted and comprehensive approaches to screening in this population. Larger studies are needed to examine the association between treatment exposures, comorbidities, and specific echocardiographic parameters (eg, LV EF, mitral E/e 0 , GLS) of cardiac dysfunction. Natriuretic peptides (BNP and NT-proBNP) are standard biomarkers used for the diagnosis and management of symptomatic heart failure in the nononcology community. 7, 8 However, because of the lack of large epidemiologic studies, current cardiology guidelines do not recommend the use of these biomarkers for primary Cardiac Disease in Lymphoma Survivors/Armenian et al Cancer February 15, 2018 screening in the asymptomatic setting. 7, 8 Protein ST2, a newer biomarker and a member of the interleukin 1 receptor family, is secreted by cultured monocytes that have been subjected to mechanical strain. 32 The ligand for this receptor is interleukin 33, which, like natriuretic peptides, is induced and released by stretched myocytes. 32 For cancer survivors who received treatment with anthracyclines, the long latency of heart failure, coupled with the cost and burden of echocardiographic screening, makes primary screening with these blood biomarkers an attractive option. In the current study, the diagnostic utility of these blood biomarkers was poor, confirming their lack of predictive value reported in other populations, such as long-term childhood cancer survivors. [33] [34] [35] [36] Unlike previous studies, 22, 37, 38 we did not observe a significant association between chest RT and cardiac dysfunction. These findings may be attributable to improvements in radiation techniques over time (eg, better shielding of the myocardium, more precise delivery to the area of disease involvement), the relatively low rate (16.1%) of chest RT use in our population, and the even lower rate (9.6%) of HD-chest RT exposure in this contemporary cohort of lymphoma survivors. It is possible that differences in chest RT exposure between the HCT and non-HCT survivors may have impacted the interpretation of our findings; the small number of survivors (N 5 3) who received treatment with chest RT and developed cardiac dysfunction limited our ability to do more detailed, dose-specific analyses. We acknowledge that the cross-sectional design of our study and the exclusion of survivors who were actively receiving treatment for heart failure limited our ability to comment on the latency and incidence of cardiac dysfunction in this cohort. That said, greater than 20% of survivors had significant asymptomatic cardiac dysfunction nearly 10 years after diagnosis, which may be an underestimate of the overall burden of cardiovascular disease in the nearly 600,000 lymphoma survivors living in the United States. 39 The current study's innovation lies in its ability to leverage existing information from nononcology populations to develop a comprehensive assessment of cardiac function, setting the stage for novel screening strategies and interventions (pharmacologic, behavioral) in highrisk survivors. In these long-term survivors, we observed a high rate of cardiac dysfunction, which was independent of HCT status, and a low yield of traditional cardiac blood biomarkers for primary screening of asymptomatic disease. The growing number of lymphoma survivors makes it imperative to identify reliable and cost-effective strategies to decrease the long-term burden of heart failure in this population.
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